Rannard SP - Search Results

1

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.

Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini GA, Owen A. Rajoli RKR, et al. Among authors: rannard sp. Br J Clin Pharmacol. 2021 Apr;87(4):2078-2088. doi: 10.1111/bcp.14619. Epub 2020 Dec 1. Br J Clin Pharmacol. 2021. PMID: 33085781 Free PMC article.

2

Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions.

Taylor J, Sharp A, Rannard SP, Arrowsmith S, McDonald TO. Taylor J, et al. Among authors: rannard sp. Nanoscale Adv. 2023 Mar 4;5(7):1870-1889. doi: 10.1039/d2na00834c. eCollection 2023 Mar 28. Nanoscale Adv. 2023. PMID: 36998665 Free PMC article. Review.

3

Nanomedicines for HIV therapy.

Siccardi M, Martin P, McDonald TO, Liptrott NJ, Giardiello M, Rannard S, Owen A. Siccardi M, et al. Ther Deliv. 2013 Feb;4(2):153-6. doi: 10.4155/tde.12.156. Ther Deliv. 2013. PMID: 23343155

4

Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.

Martin P, Giardiello M, McDonald TO, Rannard SP, Owen A. Martin P, et al. Among authors: rannard sp. Mol Pharm. 2013 Jul 1;10(7):2739-48. doi: 10.1021/mp400175n. Epub 2013 Jun 10. Mol Pharm. 2013. PMID: 23701529

5

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.

McDonald TO, Giardiello M, Martin P, Siccardi M, Liptrott NJ, Smith D, Roberts P, Curley P, Schipani A, Khoo SH, Long J, Foster AJ, Rannard SP, Owen A. McDonald TO, et al. Among authors: rannard sp. Adv Healthc Mater. 2014 Mar;3(3):400-11. doi: 10.1002/adhm.201300280. Epub 2013 Sep 1. Adv Healthc Mater. 2014. PMID: 23997027

6

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.

Liptrott NJ, Kendall E, Nieves DJ, Farrell J, Rannard S, Fernig DG, Owen A. Liptrott NJ, et al. Nanomedicine (Lond). 2014 Nov;9(16):2467-79. doi: 10.2217/nnm.14.38. Nanomedicine (Lond). 2014. PMID: 24938615

7

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.

Liptrott NJ, Giardiello M, Hunter JW, Tatham L, Tidbury LR, Siccardi M, Rannard S, Owen A. Liptrott NJ, et al. Nanomedicine (Lond). 2015 May;10(9):1407-21. doi: 10.2217/nnm.14.77. Epub 2014 Jul 23. Nanomedicine (Lond). 2015. PMID: 25055247

8

The application of nanotechnology in medicine: treatment and diagnostics.

Owen A, Dufès C, Moscatelli D, Mayes E, Lovell JF, Katti KV, Sokolov K, Mazza M, Fontaine O, Rannard S, Stone V. Owen A, et al. Nanomedicine (Lond). 2014 Jul;9(9):1291-4. doi: 10.2217/nnm.14.93. Nanomedicine (Lond). 2014. PMID: 25204820 Free article.

9

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.

Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D, Owen A. Siccardi M, et al. In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4. eCollection 2013. In Silico Pharmacol. 2013. PMID: 25505649 Free PMC article.

10

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M. Rajoli RK, et al. Clin Pharmacokinet. 2015 Jun;54(6):639-50. doi: 10.1007/s40262-014-0227-1. Clin Pharmacokinet. 2015. PMID: 25523214 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page